Q1 2017 EPS Estimates for Nektar Therapeutics Increased by Analyst (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) – Stock analysts at Jefferies Group boosted their Q1 2017 EPS estimates for shares of Nektar Therapeutics in a report released on Monday. Jefferies Group analyst D. Steinberg now anticipates that the firm will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.37). Jefferies Group currently has a “Positive” rating and a $25.00 target price on the stock. Jefferies Group also issued estimates for Nektar Therapeutics’ Q2 2017 earnings at ($0.27) EPS, Q3 2017 earnings at ($0.25) EPS, Q4 2017 earnings at $0.04 EPS, FY2017 earnings at ($0.78) EPS, FY2019 earnings at $0.65 EPS, FY2020 earnings at $1.32 EPS and FY2021 earnings at $1.68 EPS.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The company earned $37.45 million during the quarter, compared to analysts’ expectations of $40.83 million. During the same quarter in the previous year, the company earned ($0.40) EPS. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “Q1 2017 EPS Estimates for Nektar Therapeutics Increased by Analyst (NKTR)” was originally posted by Web Breaking News and is owned by of Web Breaking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at http://www.webbreakingnews.com/2017/03/25/q1-2017-eps-estimates-for-nektar-therapeutics-increased-by-analyst-nktr.html.

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Other analysts also recently issued reports about the company. Roth Capital set a $23.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a report on Saturday, March 4th. Aegis reaffirmed a “buy” rating and set a $21.00 price target on shares of Nektar Therapeutics in a report on Thursday, March 2nd. JPMorgan Chase & Co. set a $24.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a report on Tuesday. BTIG Research lifted their price target on Nektar Therapeutics from $22.00 to $27.00 and gave the stock a “positive” rating in a report on Tuesday. Finally, Piper Jaffray Companies set a $25.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday, December 12th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Nektar Therapeutics presently has an average rating of “Buy” and a consensus price target of $24.63.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 22.42 on Thursday. The stock’s market cap is $3.45 billion. The stock has a 50 day moving average price of $15.22 and a 200-day moving average price of $14.53. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $23.37.

Several hedge funds have recently bought and sold shares of NKTR. Camber Capital Management LLC boosted its stake in Nektar Therapeutics by 87.5% in the fourth quarter. Camber Capital Management LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock worth $73,620,000 after buying an additional 2,800,000 shares during the period. Norges Bank purchased a new stake in Nektar Therapeutics during the fourth quarter worth approximately $31,574,000. Numeric Investors LLC purchased a new stake in Nektar Therapeutics during the fourth quarter worth approximately $1,014,000. Thrivent Financial for Lutherans boosted its stake in Nektar Therapeutics by 16.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 82,150 shares of the biopharmaceutical company’s stock worth $1,008,000 after buying an additional 11,770 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in Nektar Therapeutics by 565.8% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 27,536 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 23,400 shares during the period. Institutional investors and hedge funds own 86.80% of the company’s stock.

In other news, CFO Gil M. Labrucherie sold 200,000 shares of Nektar Therapeutics stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $15.16, for a total transaction of $3,032,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jillian B. Thomsen sold 112,500 shares of Nektar Therapeutics stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $19.69, for a total value of $2,215,125.00. The disclosure for this sale can be found here. Insiders have sold 578,189 shares of company stock worth $8,604,153 in the last quarter. Insiders own 6.10% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.